The first patient has been treated in a first-in-human clinical trial investigating the safety and efficacy of the CXLens system, a quantitative corneal cross-linking, or qCXL, technology for noninvasive refractive vision correction.
“This milestone represents the beginning of a new era in vision correction,” Thomas Dunlap, CEO of TECLens, told Healio. “For decades, refractive procedures have relied on removing or reshaping tissue through surgery. With qCXL, we are taking a fundamentally different approach — strengthening the cornea to reshape it, without cutting or compromising its